Verified against court and regulatory records · No upfront fees · Your information is never sold
Quick Eligibility Review
Answer one question at a time. This usually takes under 2 minutes.
Check your eligibility — free
Answer 2-3 quick questions to review your potential case.
Free · Confidential · About 2 minutes · A case specialist responds within 1 business day
Your answers are never sold or shared without your consent.
The Mechanism Is Shared — Not Brand-Specific
The dental injury risk in Suboxone sublingual film arises from its formulation — specifically, from citric acid and other acidic excipients that dissolve with the film in the oral cavity, creating a low-pH environment that erodes tooth enamel. This formulation characteristic is not unique to the Suboxone brand manufactured by Indivior. Generic buprenorphine/naloxone sublingual films approved by the FDA as therapeutically equivalent to Suboxone are required to use the same route of administration (sublingual dissolution) and similar formulation parameters. Generic films contain comparable acidic excipients and produce the same oral pH environment during dissolution. The FDA's January 2022 safety communication explicitly applied to 'buprenorphine medicines dissolved in the mouth' broadly — not to Suboxone by brand name alone.
The Legal Difference: Brand vs. Generic Pharmaceutical Claims
Despite sharing the same mechanism and injury profile, claims against brand-name manufacturers and generic manufacturers are treated differently under U.S. law following the Supreme Court's decisions in PLIVA v. Mensing (2011) and Mutual Pharmaceutical Co. v. Bartlett (2013). These decisions held that generic manufacturers are federally preempted from unilaterally changing their product labels — they are required to match the brand-name label. This creates a significant legal asymmetry: if Indivior (the brand manufacturer) failed to update the Suboxone label in a timely manner, plaintiffs can pursue failure-to-warn claims against Indivior. Patients who used only generic buprenorphine film may face preemption arguments from generic manufacturers, though state-law claims and the specifics of each manufacturer's knowledge and conduct may still support recovery in some circumstances.
What Generic Users Should Know
If you used a generic buprenorphine/naloxone sublingual film and sustained significant dental injuries, you should consult with a pharmaceutical litigation attorney before concluding you have no claim. The legal landscape for generic manufacturer claims is complex but not foreclosed. Additionally, some patients used both Suboxone brand and generic film at different points in their treatment — in those cases, claims against Indivior as the brand manufacturer may be viable for the period of branded Suboxone use. An attorney can analyze your prescription history and the applicable law to identify the most viable litigation path for your specific situation.
Key data
Data & Statistics
2011
PLIVA, Inc. v. Mensing, 564 U.S. 604 (2011)
Same FDA warning
FDA Drug Safety Communication, January 12, 2022
FAQ
Frequently Asked Questions
Dive deeper
Related Guides
- Suboxone Dental Damage ExplainedSuboxone sublingual film strips damage teeth through a chemical acid erosion mechanism. Citric acid in the film creates a highly acidic oral environment during dissolution, dissolving tooth enamel with repeated daily exposure. This process is distinct from ordinary tooth decay and produces a characteristic pattern of rapid, widespread, smooth-surface erosion that dentists can document in dental records.
- Suboxone Statute of Limitations by StateSuboxone dental injury claims are subject to state product liability statutes of limitations, typically 2 to 3 years, which may run from the January 12, 2022 FDA safety communication under the discovery rule. Deadlines vary significantly by state and individual circumstances — time is critical and consultation with an attorney is the only reliable way to determine your specific deadline.
- Suboxone Dental Records and Evidence GatheringDental records — including clinical notes, X-rays, and billing documentation — are the evidentiary foundation of every Suboxone dental injury claim. Gathering them promptly is critical because dental practices have limited record retention requirements and older records may be unavailable from closed or sold practices.
- Suboxone Settlement Amounts and ExpectationsReported Suboxone dental injury settlements have ranged from approximately $35,000 for minor-to-moderate cases to $250,000 or more for complete tooth loss requiring full-mouth reconstruction. The MDL is ongoing and no global settlement has been announced — individual case values depend heavily on injury severity, documentation quality, and state-specific legal factors.
- Indivior's Failure to WarnIndivior, the manufacturer of Suboxone, had access to medical literature and adverse event data establishing the dental risk of its sublingual film formulation for years before adding dental warnings to its label. Under pharmaceutical product liability law, this gap between knowledge and disclosure forms the foundation of the failure-to-warn claims at the center of Suboxone dental injury litigation.
- The FDA Suboxone Dental Warning — January 2022On January 12, 2022, the FDA issued a formal drug safety communication confirming that buprenorphine medicines dissolved in the mouth — including Suboxone film — can cause severe dental problems. The FDA reviewed 305 adverse event reports and found widespread, serious dental injuries requiring extractions, root canals, and full reconstruction. This communication is legally significant as the potential trigger date for the statute of limitations under the discovery rule for thousands of patients.
- Suboxone Dental Injury Qualification CriteriaNot every Suboxone user who experienced dental problems has a viable legal claim. Qualifying cases generally involve significant dental injuries — multiple cavities, extractions, tooth loss, or reconstruction — developed during Suboxone use, documented in dental records, and timely filed. Understanding the criteria helps patients determine whether to pursue a claim.
- Suboxone Dental Treatment CostsDental rehabilitation costs for Suboxone-related injuries can range from several thousand dollars for restorations to $80,000 or more for full-mouth implant-supported reconstruction. These documented costs form the economic damages component of a claim and are recoverable in litigation. Understanding the cost breakdown helps patients evaluate the potential value of their claim.
- How to File a Suboxone Dental Injury LawsuitFiling a Suboxone dental injury lawsuit begins with gathering dental and prescription records, consulting a pharmaceutical litigation attorney, and submitting a complaint. Most cases are filed in or transferred to MDL 3092 in the Northern District of Ohio. The process is handled almost entirely by the attorney, under a contingency fee arrangement.
- Suboxone Class Action vs. Individual ClaimsSuboxone dental injury litigation is structured as a multidistrict litigation (MDL), not a class action. In an MDL, plaintiffs retain individual claims and individual damages — each client's recovery is based on their specific injuries, not shared with others. Understanding this distinction helps plaintiffs know what to expect from the process.
- MAT Patients and Dental StigmaPeople in recovery from opioid use disorder who experienced Suboxone-related tooth loss face a unique double stigma: societal bias against addiction, and the unfair association between visible tooth loss and substance use. These psychological and social harms are legally compensable non-economic damages, and addressing them with compassion and dignity is central to how these cases should be litigated.
The full investigation